<DOC>
	<DOCNO>NCT00588302</DOCNO>
	<brief_summary>The blockade angiotensin II synthesis attenuate hepatic fibrosis different experimental model chronic liver injury . We aim determine safety efficacy moexipril , angiotensin-converting enzyme ( ACE ) inhibitor , liver biochemistry , Mayo risk score , health-related quality life patient primary biliary cirrhosis ( PBC ) suboptimal response ursodeoxycholic acid ( UDCA ) .</brief_summary>
	<brief_title>Moexipril Primary Biliary Cirrhosis</brief_title>
	<detailed_description>Primary biliary cirrhosis ( PBC ) chronic cholestatic liver disease presume autoimmune cause characterize progressive inflammatory destruction interlobular septal bile duct , result fibrosis eventual cirrhosis ( 1 ) . In PBC patient , disable symptom fatigue pruritus diminish health-related quality life ( HRQL . Ursodeoxycholic acid ( UDCA ) , dose 13 15 mg/kg per day , safe effective medical therapy patient PBC . Nevertheless , UDCA therapy ameliorate symptom associate PBC . Some UDCA-treated patient show progressive disease result liver transplantation death liver-related cause . For patient , show persistent elevation serum alkaline phosphatase least twice normal level 6 month UDCA monotherapy ( incomplete responder ) , evaluation combination therapy clinical trial recommend . Moexipril long-acting , nonsulfhydryl ACE inhibitor lipophilicity , readily penetrate lipid membrane thus target tissue ACE addition plasma ACE . This drug also demonstrate antioxidative property addition efficiently control blood pressure hypertensive postmenopausal subject . Moreover , quality-of-life data suggest favorable effect moexipril treatment patient population high cardiovascular risk . The tolerability safety profile moexipril resemble ACE inhibitor along report hepatotoxicity control trial . Hence , moexipril attractive drug evaluation patient chronic liver disease .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Liver Cirrhosis , Biliary</mesh_term>
	<mesh_term>Moexipril</mesh_term>
	<criteria>PBC patient treat UDCA ( daily dose 13 15 mg/kg least 6 month ) incomplete response define persistent elevation serum alkaline phosphatase activity least 2 time upper limit normal age le 18 year pregnancy nursing anticipate need liver transplantation within 1 year le 80 % oneyear survival determine Mayo risk score complication cirrhosis recurrent variceal hemorrhage , portosystemic encephalopathy , refractory ascites history coexistent severe cardiovascular disease include aortic stenosis history coexistent severe renal disease ( define elevation serum creatinine 1.5 mg/dL ) include renal artery stenosis history allergy ACE inhibitor current use ACE inhibitor AT1 receptor antagonist past 3 month previous treatment immunosuppressive agent experimental drug precede 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>primary biliary cirrhosis</keyword>
	<keyword>ursodeoxycholic acid</keyword>
</DOC>